Substrate activity screening (SAS) is a fragment-based method for the rapid development of novel substrates and their conversion into non-peptidic inhibitors of Cys and Ser proteases. The method consists of three steps: (i) a library of N-acyl aminocoumarins with diverse, low-molecular-weight N-acyl groups is screened to identify protease substrates using a simple fluorescence-based assay; (ii) the identified N-acyl aminocoumarin substrates are optimized by rapid analog synthesis and evaluation; and (iii) the optimized substrates are converted into inhibitors by direct replacement of the aminocoumarin with known mechanism-based pharmacophores. This protocol describes a general procedure for the solid-phase synthesis of a library of N-acyl aminocoumarin substrates and the screening procedure to identify weak binding substrates.
INTRODUCTION
We have developed the first substrate-based fragment identification method, called 'substrate activity screening' (SAS) [1] [2] [3] . This method addresses two key challenges in fragment-based screening: (i) the accurate and efficient identification of weak binding fragments and (ii) the rapid optimization of the initial weak binding fragments into higher-affinity compounds 4, 5 . In this method ( Fig. 1) , a library of N-acyl aminocoumarins with diverse, low-molecular-weight N-acyl fragments is prepared and then, in a first step, the library is screened to identify protease substrates using a single-step, highthroughput fluorescence-based assay. The substrate-based screening method in Step 1 has important attributes in detecting weak binding fragments in addition to being high throughput and straightforward to perform. False positives as a result of aggregation, protein precipitation or non-specific binding seen in traditional inhibitor screens are not observed. In fact, in the present approach, both an active enzyme and productive active-site binding are required for the protease-catalyzed amide bond hydrolysis to occur and for the subsequent release of the fluorescent coumarin group to be observed. In addition, in contrast to direct binding assays and traditional inhibitor screens, catalytic substrate turnover results in signal amplification, and therefore even very weak substrates can be identified at concentrations where only minimal binding to the enzyme occurs. The second and third steps ( Fig. 1) , which are not covered in this protocol, provide a strategy for systematically and efficiently optimizing substrates incorporating weak binding fragments into high-affinity inhibitors. In the second step, the activity of the substrates is rapidly optimized by the straightforward solidphase synthesis and subsequent assay of focused libraries of substrate analogs. The third step then builds upon a key attribute of this mechanism-based substrate screen, namely, that the N-acyl aminocoumarin must be precisely oriented in the active site to enable productive substrate cleavage and, therefore, that the aminocoumarin can be replaced with mechanism-based pharmacophores to provide protease inhibitors directly. The choice and the versatility of pharmacophores allow reversible or irreversible inhibitors to be obtained rapidly once efficient substrates are identified.
We have successfully applied the SAS method to both Cys and Ser protease targets to identify novel, low-molecular-weight substrates and have subsequently optimized and converted the substrates into potent, non-peptidic inhibitors [1] [2] [3] . The SAS method was initially successfully applied to the identification of two distinct classes of novel, non-peptidic inhibitors with nanomolar affinity to cathepsin S, which is an enzyme implicated in a number of autoinflammatory diseases (Fig. 2) 6 . In the first step, a diverse library of N-acyl 7-amino-4-methylcoumarin acetic acid (AMCA) derivatives was screened to identify multiple distinct substrate classes. In the second step, substrate optimization by rapid analog synthesis and Weak protease substrates identified
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Step 3 evaluation resulted in substrates with more than 8,000-fold increases in cleavage efficiency relative to the initial substrates. Direct conversion of the substrates into inhibitors was then accomplished simply by replacing the aminocoumarin with a hydrogen atom to introduce the aldehyde mechanism-based pharmacophore 1 . The novel inhibitors that resulted from this process are distinct from previously reported inhibitors of cathepsin S 6, 7 . Using the SAS method and guided by the crystal structure of a triazole inhibitor bound to cathepsin S, we increased the activity of the 1,4-disubstituted-1,2,3-triazole-based substrates tenfold. Conversion into inhibitors with the clinically validated nitrile pharmacophore 8 provided potent inhibitors (K i ¼ 15 nM for cathepsin S) with more than 1,000-fold selectivity over the closely related cathepsins B, K and L 2 . This method is also applicable to Ser proteases, as demonstrated for the prototypical Ser protease chymotrypsin. Specifically, a novel, potent and completely non-peptidic irreversible inhibitor of chymotrypsin was discovered that had excellent selectivity over the related Ser proteases, namely, cathepsin G, elastase and trypsin 3 . These results demonstrate that potent and selective nonpeptidic inhibitors of distinct classes of proteases can be obtained using this substrate-based method for fragment identification and optimization. In this protocol, the synthesis of a diverse, low-molecular-weight N-acyl aminocoumarin library and the screening procedure against a protease target is described. A library of N-acyl aminocoumarins (5) can be prepared according to the procedure shown in Figure 3 . In the first step, 9-fluorenylmethyloxycarbonyl (Fmoc)-protected AMCA (Fmoc-AMCA, 7), which can easily be synthesized according to the method shown in Figure 4 , is loaded onto Wang resin to provide the support-bound aminocoumarin 2. The AMCA fluorogenic group was chosen because it is bifunctional and therefore suitable for rapid solid-phase synthesis. In addition, the AMCA coumarin showed greater sensitivity and higher solubility than other coumarins in the substrate assay. Wang resin was chosen as the solid-support because it allows for easy access to substrates with a free carboxylic acid. In general, however, any aminocoumarin and solid-support could be chosen. In the second step of the N-acyl aminocoumarin synthesis, the Fmoc group can be removed to liberate aminocoumarin 3, which can then be acylated with diverse carboxylic acids and further derivatized, if desired, to yield the support-bound coumarin 4. The carboxylic acid inputs should be of low molecular weight (less than 300 Da), compatible with the solid-phase synthetic scheme, and either commercially available or easily obtained using synthetic methods. The general procedure below is for the synthesis of one library member. To synthesize the full library of N-acyl aminocoumarin substrates, Fmoc-AMCAWang resin (2) should be prepared on a larger scale and split into portions for each substrate to be synthesized. Note that Steps 31-54 in the procedure can easily be conducted in parallel to expedite synthesis. Following acidic cleavage from support and purification, a diverse library of N-acyl aminocoumarins (5) is obtained. The screening procedure described is for cathepsin S but should be easily modifiable to be applicable to any Cys or Ser protease because peptidyl coumarin fluorogenic substrates have been shown to be efficiently cleaved by a very large number of diverse Cys and Ser proteases 9 . In designing the substrate assay, a number of items are of great importance. First, an appropriate buffer must be chosen. This will usually be the buffer that is optimal for known peptidic substrates, but modification may be needed owing to N-acyl aminocoumarin solubility. Second, the proper substrate concentration in the assay must be identified. In general, the highest substrate concentration for which none of the substrates precipitates/ aggregates is best for identifying the greatest Step 1 Assayed against cathepsin S
Step 2 Focused substrate library synthesized and screened
Step 3 Converted substrates into inhibitors >8,000-fold more efficient substrates identified number of weak binding substrates. This concentration may vary based on the buffer chosen and average solubility of the library members. In addition, a small peptidic N-acyl aminocoumarin substrate, either a mono-or dipeptidic substrate, that is cleaved by the protease under the assay conditions should be identified and included in each assay as a positive control. For cathepsin S, the positive control was Bz-Gly-AMCA, which served as an ideal substrate because complete substrate consumption is not observed over the course of the assay. Finally, a proper concentration of protease must be chosen. For cathepsin S and chymotrypsin, the substrate library was first screened at an enzyme concentration 500-to 1,000-fold lower than that of the substrate, but for less active enzymes, a higher concentration of enzyme might be required. This protocol describes the procedure for assaying 19 N-acyl aminocoumarins in duplicate against cathepsin S (one 96-well plate), which can be repeated or conducted in parallel to assay a larger N-acyl aminocoumarin library. The second and third steps of the SAS method ( Fig. 1) are not explicitly described in this protocol, as optimization of lead substrates and inhibitor synthesis will vary greatly depending on the structure of the lead substrate.
After screening the diverse library, optimization of weak substrates into potent substrates (step 2 in Fig. 1 ) can be performed before converting substrates into inhibitors because transition-state theory for enzyme-catalyzed reactions predicts that the inhibitory activity (K i ) of mechanism-based inhibitors can be correlated with the inverse of the catalytic efficiency of the corresponding substrates (K m /k cat ) 10 . Other researchers have confirmed this correlation for peptide substrates 11, 12 , and we have observed this correlation for non-peptidic substrates and inhibitors for both cathepsin S and chymotrypsin [1] [2] [3] . To obtain accurate relative substrate cleavage efficiencies (k cat /K m ) in the substrate optimization step, assays should be conducted at substrate concentrations below the K m of the substrates (Michaelis-Menten equation:
). This can be accomplished by periodically determining an approximate K m for the most potent substrate(s) in a series. In the third step of the SAS method ( Fig. 1) , the selection of a pharmacophore for inhibitors will depend upon the protease of interest. For example, for cathepsin S and other papain-family Cys proteases, aldehyde, ketone, nitrile and arylaminoethyl amide groups are documented to be viable reversible pharmacophores [13] [14] [15] , whereas chloromethyl ketones are documented as general irreversible inhibitor pharmacophores for X-ray crystallographic study 16 .
MATERIALS

REAGENTS
. Dichloromethane (CH 2 Cl 2 ; Fisher, cat. no. D143-4) m CRITICAL When specified, CH 2 Cl 2 is purified by distillation over calcium hydride to remove water.
. Chlorotrimethylsilane (TMSCl; Sigma-Aldrich, cat. no. 386529) . Diisopropylethylamine (i-Pr 2 EtN; Fluka, cat. no. 03440) m CRITICAL When specified, i-Pr 2 EtN is purified by distillation over calcium hydride to remove water.
. Pyridine (Sigma-Aldrich, cat. no. 360570) m CRITICAL When specified, pyridine is purified by distillation over calcium hydride to remove water.
. Calcium hydride (Aldrich, cat. no. 558257) ! CAUTION Calcium hydride is a flammable solid and is water reactive.
. AMCA (Fluka, cat. no. 08445); can be synthesized analogously to the synthesis of 7-amino-4-carbamoylmethylcoumarin (ACC) 17 . . Cathepsin S, from human spleen (CalBioChem, cat. no. 219344) . Buffers (see REAGENT SETUP)
EQUIPMENT
. 100-ml 24/40 round-bottomed flask (Fisher, cat. no. 10-067C) . 1,000-ml side-armed flask (Fisher, cat. no. 10-180F) . 250-ml separatory funnel (Fisher, cat. no. 10-437C) . 250-ml Erlenmeyer flask (Fisher, cat. no. 10-040F) . 4 . Teflon stopcocks (Applied Separations, cat. no. 2406) . Tygon tubing (Fisher, cat. no. 14-169-1K) . Polypropylene plastic syringes (Fisher, 1 ml, cat. no. 14-817-25; 10 ml, cat. no. 14-817-31; 50 ml, cat. no. 14-817-40)
. 18 
PROCEDURE
Synthesis of Fmoc-AMCA TIMING 22 h 1| Fit a 100-ml round-bottomed flask with a Teflon-coated magnetic stir bar and a reflux condenser capped with a rubber septum.
2| Remove the syringe plunger from a 1-ml plastic polypropylene syringe and cut off the top of the syringe barrel using a pair of scissors. Insert the syringe into one end of Tygon tubing and connect the other end to a vacuum manifold. Attach a disposable syringe needle to the end of the 1-ml syringe barrel and insert the needle into the septum on the reflux condenser.
3| Put the system under vacuum and flame-dry the round-bottomed flask, stir bar and reflux condenser. 6| Add 35 ml distilled CH 2 Cl 2 , using a needle attached to a 50-ml plastic syringe, via the septum on the condenser, to make a 0.60 M solution. Turn the magnetic stirrer on.
7| Add 6.1 ml (48 mmol, 2.3 equiv.) distilled TMSCl and 8.4 ml (48 mmol, 2.3 equiv.) distilled i-Pr 2 EtN, using a needle attached to 10-ml plastic syringes, via the septum on the condenser. m CRITICAL STEP It is important to use freshly distilled TMSCl to obtain a high reaction yield.
8|
Heat the reaction flask to 70 1C so that the reaction solution refluxes. Heat for 3 h.
9|
Remove the heating source, allow the flask to cool to room temperature and then cool the flask in an ice-water bath.
10| Remove commercially available Fmoc-Cl from storage in a -20 1C freezer. After the container warms to room temperature, weigh 6.2 g (24 mmol, 1.1 equiv.) Fmoc-Cl and add in five portions over 15 min to the round-bottomed flask by quickly removing the condenser for each addition. ' PAUSE POINT Remove the ice-water bath and stir the reaction mixture for 15 h at room temperature.
11| With vigorous stirring, add 130 ml MeOH. Fmoc-AMCA (7) will precipitate as a white solid.
12| Filter the mixture through filter paper in a Büchner funnel attached to a 1,000-ml sidearm flask connected to vacuum.
13| Wash the solid with 100 ml MeOH in two portions and then with 750 ml Et 2 O in four portions.
14| Collect the solid Fmoc-AMCA (7) and dry it under vacuum. ' PAUSE POINT Fmoc-AMCA (7) 17| Place 0.20 mmol (1.0 equiv.) Wang resin (1) in the cartridge. The loading of the commercial resin we have used has ranged between 0.90 and 1.3 mmol g À1 . Please note that this reaction has been performed on as much as 10 g resin.
18|
To wash the resin, add 5 ml DMF to the resin. After 2 min, open the stopcock to remove the DMF, and re-close the stopcock. Wash the resin with DMF two more times.
19|
In a vial, add 1.5 ml DMF to 210 mg (0.46 mmol, 2.3 equiv.) Fmoc-AMCA (7) to make a 0.30 M solution. Add 62 ml (0.76 mmol, 3.8 equiv.) distilled pyridine to this solution and mix until Fmoc-AMCA is completely dissolved. Add this solution to the resin.
20| Slowly add (dropwise) 66 ml (0.46 mmol, 2.3 equiv.) 2,6-dichlorobenzoyl chloride to the cartridge. ! CAUTION 2,6-Dichlorobenzoyl chloride is a corrosive liquid.
21|
Remove the plunger from a 10-ml plastic syringe and insert it securely into the polypropylene cartridge. Remove the cartridge from the vacuum manifold and place cartridge horizontally on an orbital shaker. ' PAUSE POINT Turn the shaker on and gently shake the cartridge for 24-48 h.
22| Remove the plunger from the cartridge and connect the cartridge to the vacuum manifold. Turn on the vacuum.
23|
Open the stopcock on the cartridge and remove the Fmoc-AMCA solution.
24| Wash the resin three times with 5 ml DMF.
25| Wash the resin three times with 5 ml THF.
26| Wash the resin three times with 5 ml MeOH.
27| Wash the resin three times with 5 ml THF.
28| Wash the resin three times with 5 ml CH 2 Cl 2 .
29| Dry the resin in the cartridge under vacuum. ' PAUSE POINT Fmoc-AMCA-Wang resin (2) can be stored indefinitely at -20 1C after all solvent is removed.
30| Determine the loading of the resin by Fmoc quantitation 18, 19 . ? TROUBLESHOOTING Fmoc de-protection TIMING 30 min 31| Remove Fmoc-AMCA-Wang resin (2) from the -20 1C freezer and allow it to warm to room temperature.
32| Measure out 0.10 mmol Fmoc-AMCA-Wang resin (2) based on the loading determined by Fmoc quantitation and place in a cartridge equipped with a stopcock and attached to the vacuum manifold.
33| Wash the resin three times with 5 ml DMF.
34| Make a 20% solution of piperidine with 2.0 ml piperidine and 8.0 ml DMF. Add 5 ml of this solution to the cartridge. Remove the cartridge from the vacuum manifold, insert a plunger and place the cartridge horizontally on an orbital shaker. Shake gently for 5 min.
35| Remove the plunger from the cartridge and connect the cartridge to the vacuum manifold. Turn on the vacuum and open the stopcock on the cartridge to remove the piperidine solution.
36| Wash the resin one time with 5 ml DMF.
37| Repeat Steps 34-35.
38| Wash the AMCA-Wang resin (3) three times with 5 ml DMF.
Loading carboxylic acids onto AMCA-Wang resin TIMING 26 h 39| Remove HATU from refrigerator and allow it to warm to room temperature. 43| Wash the resin one time with 5 ml DMF.
44| Repeat Steps 39-42.
45| Wash the resin three times with 5 ml DMF.
46| Wash the resin three times with 5 ml THF.
47| Wash the resin three times with 5 ml MeOH.
48| Wash the resin three times with 5 ml THF.
49| Wash the resin three times with 5 ml CH 2 Cl 2 .
Support cleavage and purification of product TIMING 27 h 50| Prepare a 10-ml cleavage solution of 9:1 CH 2 Cl 2 :(95% TFA, 2.5% deionized water, 2.5% TIS) vol/vol. Add 5 ml cleavage solution to the resin and remove the cartridge from the vacuum manifold, insert a plunger and place cartridge horizontally on an orbital shaker. Shake for 1-2 h. ! CAUTION TFA is corrosive.
51| Remove the plunger from the cartridge and drain the cleavage solution into a 100-ml round-bottomed flask.
52| Close stopcock and add 5 ml cleavage solution to the resin. Wait for 2 min and then drain the solution from the cartridge into the round-bottomed flask.
53| Close the stopcock and add 5 ml CH 2 Cl 2 . Wait for 2 min and then drain the solution from the cartridge into the roundbottomed flask. Repeat the CH 2 Cl 2 rinse two more times.
54| Combine the washes from Steps 51-53 and concentrate in a water bath heated to 40 1C, using a rotary evaporator under reduced pressure. ' PAUSE POINT The crude product can be stored at -20 1C for at least 1 month.
55| Dissolve the crude product in the minimal amount of MeCN. Add water until the solution becomes cloudy. Add MeCN until the solution is clear. For compounds with poor solubility (compounds that require more than 5 ml solvent to dissolve), the crude material can be dissolved in DMSO. Draw the entire solution into a 10-ml syringe using a syringe needle. Remove the syringe needle and attach a 0.45-mm syringe filter. Expel the sample through the filter into a vial to remove particulates before injecting onto the HPLC. Withdraw the entire solution into a 10 ml polypropylene syringe using an attached HPLC needle and expel the air bubbles from the syringe.
56| Inject the sample into the injection loop of the HPLC instrument. Carry out HPLC purification using a gradient of 5:95-95:5 MeCN:water at 8 ml per minute over 50 min and monitor at 254 nm. After the run has finished, pool the fractions for each peak on the chromatogram. Conduct mass spectrometry on each peak to identify the desired product. For the most part, the peak with the greatest area is the desired product. Note that depending on the product mixture, the gradient may need to be adjusted.
57|
Transfer the combined product fractions for the desired product to an appropriately sized round-bottomed flask and remove the excess MeCN and TFA by heating in a 40 1C water bath, using a rotary evaporator under reduced pressure. Be careful not to remove all the H 2 O.
58| Transfer the remaining aqueous solution to a 50-ml centrifuge tube and freeze the sample by placing the tube in liquid nitrogen or in a -78 1C freezer.
59| Remove the frozen solvent using a freeze-dry system to obtain the desired N-acyl aminocoumarin product (5). Preparing assay solutions for library screening TIMING 1 h 61| Dissolve purified N-acyl aminocoumarins (5) in DMSO, dispensed using a micropipette with a disposable pipette tip, to make a 10 mM stock solution. ! CAUTION Use appropriate gloves when handling DMSO solutions because DMSO can transport organic molecules into the body. ' PAUSE POINT N-acyl aminocoumarin solutions can be stored indefinitely at -20 1C.
62| Prepare buffer B: using a micropipette, dispense a portion of cathepsin S stock solution into 2 ml of buffer A in a 15-ml centrifuge tube. Note that cathepsin S solutions may be kept in an ice-water bath for approximately 1 h without appreciable loss of enzyme activity. m CRITICAL STEP To prevent enzyme inactivation, avoid repeated freeze/thaw cycles and extended exposure to temperatures above -78 1C.
Preparing 96-well microtiter plate for assay TIMING 30 min 63| Using a micropipette, add 38 ml buffer A to two wells of the 96-well plate (yellow wells, Fig. 5 ) for each N-acyl aminocoumarin (S1-S19) and Bz-Gly-AMCA (this peptidyl coumarin serves as a suitable positive control substrate for papainfamily Cys proteases, but a different positive control peptide substrate will likely be required for other protease classes). Note that Bz-Gly-AMCA can be prepared using standard Fmoc-based solid-phase peptide coupling strategies and should be assayed at the same concentration as the N-acyl aminocoumarins being tested 17 .
64| Using a micropipette, add 2 ml of each N-acyl aminocoumarin DMSO solution (S1-S19 and Bz-Gly-AMCA) to two wells in the 96-well plate containing buffer A (yellow wells, Fig. 5 ) to make a solution that is 500 mM in N-acyl aminocoumarin.
? TROUBLESHOOTING 65| Using a micropipette, add 38 ml buffer B to two wells of the 96-well plate (red wells, Fig. 5 ) for each N-acyl aminocoumarin (S1-S19) and Bz-Gly-AMCA (control).
66| Using a micropipette, add 2 ml of each N-acyl aminocoumarin DMSO solution (S1-S19 and Bz-Gly-AMCA) to two wells in the 96-well plate containing buffer B (red wells, Fig. 5 ) to make a solution that is 500 mM in N-acyl aminocoumarin and 750 nM in cathepsin S. m CRITICAL STEP Ensure proper mixing between buffer solution and DMSO solution.
Assay N-acyl aminocoumarins TIMING 6 h 67| Place a thermal adhesive sealing film on the microtiter plate and incubate the plate for 15 min at 37 1C. m CRITICAL STEP To limit evaporation of the assay solutions, form a tight seal between the microtiter plate and the adhesive film.
68| Remove the adhesive film and perform a fluorescent reading of columns 2-11 of the 96-well plate.
69| Replace the thermal adhesive sealing film and incubate at 37 1C. 72| For each N-acyl aminocoumarin, construct a plot of RFU versus time. For active substrates, a fluorescent signal over background will be observed (Fig. 6) . B  C  D  E  F  G  H   S1  S1  S1  S1  S2  S2  S2  S2   S3  S3  S3  S3  S4  S4  S4  S4   S5  S5  S5  S5  S6  S6  S6  S6   S7  S7  S7  S7  S8  S8  S8  S8 S9 S9 S9 S9 S10 S10 S10 S10 S11 S11 S11 S11 S12 S12 S12 S12 S13 S13 S13 S13 S14 S14 S14 S14 S15 S15 S15 S15 S16 S16 S16 S16 S17 S17 S17 S17 S18 S18 S18 S18 S19 S19 S19 S19 control control control control m CRITICAL STEP Ensure that substrate cleavage of the positive control (Bz-Gly-AMCA) is detected (see Fig. 6d) Step Problem Possible reasons Possible solutions Library synthesis Step 14 Low yields of Fmoc-AMCA (7) Acidic impurity of reagents, particularly TMSCl
Repeat reaction with freshly distilled TMSCl
Step 30 Low yields of Fmoc-AMCA-Wang resin (2) Reagents, particularly 2,6-dichlorobenzoyl chloride
Repeat reaction with new reagent
Step 60 Low or no product yields of N-acyl aminocoumarins (5)
Carboxylic acid is not compatible with the solid-phase method (may be piperidine or TFA sensitive)
Change the solid-phase method. First perform control sequence to prepare a known N-acyl aminocoumarin product
Library screening
Step 64
Suspension forms immediately in assay well
Substrates are insoluble in this buffer at this concentration
Change buffer conditions for all N-acyl aminocoumarins Decrease concentration for some or all N-acyl aminocoumarins
Step 70 Formation of suspension in assay well between 0 and 6 h of incubation Evaporation of buffer Use fresh adhesive films after each reading and ensure a tight seal before re-incubation. Do not use columns 1 and 12 of the assay plate Increase the total volume in each assay well (scaling all components accordingly)
Step 
Library Screening
With a diverse N-acyl aminocoumarin library of approximately 100 compounds, synthesized from small, commercially available or easily synthesized carboxylic acid precursors, we identified three distinct lead substrates for cathepsin S. Results will vary depending on the protease target and the diversity of the library. 
